Efecto de los inhibidores JAK en lipoproteínas de alta y baja densidad en pacientes con artritis reumatoide: una revisión sistemática y metanálisis
Clin Rheumatol. 2022. Epub ahead of print doi: 10.1007/s10067-021-06003-z
Systematic review and network meta-analysis highlight that RA patients who receive recommended doses of the five approved JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib, and peficitinib) are likely to experience an increase in serum low- and high-density lipoprotein (LDL and HDL) levels.JAK inhibitors have been associated with alterations in levels of LDL and HDL cholesterol, which may lead to dyslipidaemia (an important risk factor for cardiovascular disease). However, the e...